

For Immediate Release

TSX Exchange Symbol: RVX

Resverlogix Notice of Conference Call & Webcast for Year End Update

May 10, 2010 (Calgary, AB) — Resverlogix Corp. (TSX:RVX) announced today that it will host a live teleconference and webcast on Wednesday, May 12, 2010 at 1:00 pm Eastern/11:00 am Mountain time. The purpose of the teleconference is to provide a corporate and clinical update. There will be a slide presentation followed by a question and answer session regarding the impact of the early completion of the ASSERT trial in addition to an update of the ASSURE trial.

The dial-in numbers for this event are toll free 1-800-319-4610 and international 1-604-638-5340. A link for this webcast will be posted onto the homepage of Resverlogix's website and can be accessed from the following address <http://services.choruscall.com/links/resverlogix100511.html>.

The webcast will be available on the Resverlogix website for replay for a period of 45 days after the event.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas™ PR program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

For further information please contact:

Theresa Kennedy
VP, Corporate Communications
Resverlogix Corp.
Phone: 604-538-7072
Fax: 403-256-8495
Email: Theresa@resverlogix.com

Sarah Zapotichny
Manager Investor Relations
Resverlogix Corp.
Phone: 403-254-9252
Fax: 403-256-8495
Email: Sarah@resverlogix.com

US Investor Relations

Susan Noonan
Managing Partner
S.A. Noonan Communications, LLC
Phone: 212-966-3650
Email: susan@sanoonan.com

US Media Relations

Eric Goldman
Vice President
Rx Communications Group
Phone: 917-322-2563
Email: egoldman@rxir.com